Genome Editing Global Market - Forecast to 2022
Ever since the establishment of the genetic basis of life, researchers have tried to manipulate genes in plants and animals to improve traits. There has been a continuous evolution of gene modification technique starting from restriction endonucleases, transgenic breeding, RNAi technologies to the current engineered endonucleases. Over the last several decades, technologies for identification, isolation, sequencing, replication and integration of desired genes in target organisms have transformed tremendously and emerged as one of the exciting and significant areas of scientific endeavour.
The Genome editing global market is segmented based on technology, applications, products, end users and geography. Technologies segment consists of Zinc Finger Nucleases (ZFN), Transcriptor-activator-like effector nuclease (TALEN); Clustered regularly interspaced short palindromic repeats (CRISPR) and other gene modification techniques such as Recombinant adeno-associated virus (rAAV), piggyBac transposon, megatales etc. Applications identified includes, basic research, agriculture biotechnology, animal research, drug discovery and development. Products are classified into reagents, enzymes and consumables, instruments, cell lines & animal models and software. Depending on the end users, the genome editing global market is sectioned into academic & government institutions, pharmaceutical & biotechnology companies, plant biotechnology and others.
This report studies the genome editing global market over the forecast period 2015 to 2022 and the market is expected to grow at high double digit CAGR to reach $2,669.9 million by 2022. Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene-edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo and adverse public perception, unavailability of gene-editing based therapeutics in the market, off-target effects of CRISPR and patent disputes associated with CRISPR technology are hampering the market growth.
Geographically, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America dominated the genome editing market with the largest share which is driven by factors such as increasing awareness of technology, proximity of companies, and early adoption of latest treatments. The Asian market is expected to occupy second place due increasing government funding of research, economic prosperity, early adoption of latest technology and the relaxed regulatory environment. The European market is expected to be third largest market, growing at a lower rate mainly due to the stringent regulatory environment and slow growth due to the economic crisis.
The genome editing global market is a consolidated market with key players such as Applied Stemcell (U.S.), Cellectis S.A. (France), Genscript (U.S.), Horizon Discovery Group (U.K.), Merck KGaA (Germany), Origene Technologies (U.S.), Sangamo Biosciences (U.S.), System Biosciences (U.S.), Thermo Fisher Scientific (U,S,), Transposagen (U.S.).
The Genome editing global market is segmented based on technology, applications, products, end users and geography. Technologies segment consists of Zinc Finger Nucleases (ZFN), Transcriptor-activator-like effector nuclease (TALEN); Clustered regularly interspaced short palindromic repeats (CRISPR) and other gene modification techniques such as Recombinant adeno-associated virus (rAAV), piggyBac transposon, megatales etc. Applications identified includes, basic research, agriculture biotechnology, animal research, drug discovery and development. Products are classified into reagents, enzymes and consumables, instruments, cell lines & animal models and software. Depending on the end users, the genome editing global market is sectioned into academic & government institutions, pharmaceutical & biotechnology companies, plant biotechnology and others.
This report studies the genome editing global market over the forecast period 2015 to 2022 and the market is expected to grow at high double digit CAGR to reach $2,669.9 million by 2022. Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene-edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo and adverse public perception, unavailability of gene-editing based therapeutics in the market, off-target effects of CRISPR and patent disputes associated with CRISPR technology are hampering the market growth.
Geographically, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America dominated the genome editing market with the largest share which is driven by factors such as increasing awareness of technology, proximity of companies, and early adoption of latest treatments. The Asian market is expected to occupy second place due increasing government funding of research, economic prosperity, early adoption of latest technology and the relaxed regulatory environment. The European market is expected to be third largest market, growing at a lower rate mainly due to the stringent regulatory environment and slow growth due to the economic crisis.
The genome editing global market is a consolidated market with key players such as Applied Stemcell (U.S.), Cellectis S.A. (France), Genscript (U.S.), Horizon Discovery Group (U.K.), Merck KGaA (Germany), Origene Technologies (U.S.), Sangamo Biosciences (U.S.), System Biosciences (U.S.), Thermo Fisher Scientific (U,S,), Transposagen (U.S.).
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN & DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.4 MARKET DYNAMICS
3.4.1 DRIVERS AND OPPORTUNITIES
3.4.1.1 Increased R&D expenditure and growth of biotechnology and pharmaceutical industries.
3.4.1.2 Investments from both public and private sectors for gene-editing technology
3.4.1.3 Technological advancements in sequencing and gene editing technologies
3.4.1.4 Non-transgenic breeding technologies and gene-edited plants not labelled as GMO in many countries
3.4.1.5 Improvement in drug discovery process
3.4.1.6 Varied applications in drug discovery and development, plant engineering, improvement in animal traits, therapeutics
3.4.1.7 Precision medicine and new therapeutics for genetic and other disorders
3.4.2 RESTRAINTS AND THREATS
3.4.2.1 Stringent regulatory frameworks
3.4.2.2 Ethical issues concerning editing human embryo and adverse public perception
3.4.2.3 Unavailability of gene-editing based therapeutic product in the market and less geographic penetration due to uncertain regulations
3.4.2.4 Patent dispute associated with CRISPR/CAS
3.4.2.5 Off-target effects of CRISPR/CAS9 genome editing technology
3.5 PORTER’S FIVE FORCE ANALYSIS
3.5.1 THREAT OF NEW ENTRANTS
3.5.2 THREAT OF SUBSTITUTES
3.5.3 BARGAINING POWER OF SUPPLIERS
3.5.4 BARGAINING POWER OF BUYERS
3.5.5 RIVALRY AMONG EXISTING COMPETITORS
3.6 REGULATORY AFFAIRS
3.6.1 NORTH AMERICA
3.6.2 EUROPE
3.6.3 CHINA
3.6.4 JAPAN
3.6.5 INDIA
3.6.6 LATIN AMERICA
3.7 PATENT ANALYSIS
3.8 FUNDING SCENARIO
3.9 COLLABORATION, JOINT VENTURE, PARTNERSHIP, AGREEMENT
3.10 MARKET SHARE ANALYSIS
4 GENOME EDITING GLOBAL MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.2 ZINC FINGER NUCLEASE (ZFN)
4.3 TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALEN)
4.4 CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR/CAS9)
4.4.1 WT CRISPR/CAS9
4.4.2 CRISPR/CAS9 NICKASE
4.4.3 CRISPR DCAS9
4.5 OTHERS
4.5.1 RECOMBINANT ADENO-ASSOCIATED VIRUS (R AAV)
4.5.2 PIGGYBAC TRANSPOSASE AND SLEEPING BEAUTY TRANSPOSON
4.5.3 ARCUS (HOMING ENDONUCLEASE) AND MEGATAL
4.5.4 TARGATT AND RAPID TRAIT DEVELOPMENT SYSTEM (RTDS)
5 GENOME EDITING GLOBAL MARKET, BY APPLICATION
5.1 INTRODUCTION
5.2 BASIC RESEARCH
5.2.1 TRANSCRIPTION ACTIVATION/REPRESSION
5.2.2 GENOMIC SCREENING
5.2.3 GENOMIC VISUALIZATION
5.3 PLANT BIOTECHNOLOGY/AGRICULTURE
5.4 ANIMAL BIOTECHNOLOGY
5.4.1 ANIMAL HEALTH
5.4.2 LIVESTOCK
5.4.3 OTHER
5.5 DRUG DISCOVERY AND DEVELOPMENT
5.5.1 PRE-CLINICAL
5.5.2 CLINICAL
6 GENOME EDITING GLOBAL MARKET, BY PRODUCTS AND SERVICES
6.1 INTRODUCTION
6.2 REAGENTS, ENZYMES AND CONSUMABLES
6.2.1 GENOME EDITING TOOLS AND KITS
6.2.2 DELIVERY TOOLS
6.2.3 OTHER REAGENTS, ENZYMES AND CONSUMABLES
6.3 CELL LINES AND ANIMAL MODELS
6.4 GENOME EDITING SERVICES
6.5 INSTRUMENTS
6.6 SOFTWARE
7 GENOME EDITING GLOBAL MARKET, BY END USERS
7.1 INTRODUCTION
7.2 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
7.3 PLANT BIOTECHNOLOGY COMPANIES
7.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
7.5 OTHERS
7.5.1 ANIMAL BIOTECHNOLOGY
7.5.2 CONTRACT RESEARCH ORGANIZATIONS (CRO)
8 GENOME EDITING GLOBAL MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 U.S.
8.3 EUROPE
8.4 ASIA-PACIFIC
8.4.1 CHINA
8.4.2 JAPAN
8.4.3 INDIA
8.5 REST OF THE WORLD (ROW)
8.5.1 LATIN AMERICA
8.5.2 MIDDLE EAST
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.1.1 LICENSING AGREEMENT AND OTHERS AS A MAJOR GROWTH
STRATEGY OF MARKET PLAYERS
9.2 LICENSING AGREEMENT
9.3 OTHER DEVELOPMENTS
9.4 AGREEMENT/COLLABORATION/PARTNERSHIP/JOINT VENTURE
9.5 APPROVAL
9.6 NEW PRODUCT LAUNCH
9.7 ACQUISITIONS
10 MAJOR COMPANIES
10.1 APPLIED STEMCELL INC.
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCT PORTFOLIO
10.1.4 KEY DEVELOPMENTS
10.1.5 BUSINESS STRATEGY
10.1.6 SWOT ANALYSIS
10.2 CELLECTIS S.A.
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCT PORTFOLIO
10.2.4 KEY DEVELOPMENTS
10.2.5 BUSINESS STRATEGY
10.2.6 SWOT ANALYSIS
10.3 GENSCRIPT BIOTECH CORPORATION
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCT PORTFOLIO
10.3.4 KEY DEVELOPMENTS
10.3.5 BUSINESS STRATEGY
10.3.6 SWOT ANALYSIS
10.4 HORIZON DISCOVERY GROUP, PLC
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCT PORTFOLIO
10.4.4 KEY DEVELOPMENTS
10.4.5 BUSINESS STRATEGY
10.4.6 SWOT ANALYSIS
10.5 MERCK KGAA
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCT PORTFOLIO
10.5.4 KEY DEVELOPMENTS
10.5.5 BUSINESS STRATEGY
10.5.6 SWOT ANALYSIS
10.6 ORIGENE TECHNOLOGIES, INC.
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCT PORTFOLIO
10.6.4 KEY DEVELOPMENTS
10.6.5 BUSINESS STRATEGY
10.6.6 SWOT ANALYSIS
10.7 SANGAMO BIOSCIENCES
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCT PORTFOLIO
10.7.4 KEY DEVELOPMENTS
10.7.5 BUSINESS STRATEGY
10.7.6 SWOT ANALYSIS
10.8 SYSTEM BIOSCIENCES
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCT PORTFOLIO
10.8.4 KEY DEVELOPMENTS
10.8.5 BUSINESS STRATEGY
10.8.6 SWOT ANALYSIS
10.9 THERMO FISHER SCIENTIFIC INC.
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCT PORTFOLIO
10.9.4 KEY DEVELOPMENTS
10.9.5 BUSINESS STRATEGY
10.9.6 SWOT ANALYSIS
10.10 TRANSPOSAGEN
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCT PORTFOLIO
10.10.4 KEY DEVELOPMENTS
10.10.5 BUSINESS STRATEGY
10.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN & DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.4 MARKET DYNAMICS
3.4.1 DRIVERS AND OPPORTUNITIES
3.4.1.1 Increased R&D expenditure and growth of biotechnology and pharmaceutical industries.
3.4.1.2 Investments from both public and private sectors for gene-editing technology
3.4.1.3 Technological advancements in sequencing and gene editing technologies
3.4.1.4 Non-transgenic breeding technologies and gene-edited plants not labelled as GMO in many countries
3.4.1.5 Improvement in drug discovery process
3.4.1.6 Varied applications in drug discovery and development, plant engineering, improvement in animal traits, therapeutics
3.4.1.7 Precision medicine and new therapeutics for genetic and other disorders
3.4.2 RESTRAINTS AND THREATS
3.4.2.1 Stringent regulatory frameworks
3.4.2.2 Ethical issues concerning editing human embryo and adverse public perception
3.4.2.3 Unavailability of gene-editing based therapeutic product in the market and less geographic penetration due to uncertain regulations
3.4.2.4 Patent dispute associated with CRISPR/CAS
3.4.2.5 Off-target effects of CRISPR/CAS9 genome editing technology
3.5 PORTER’S FIVE FORCE ANALYSIS
3.5.1 THREAT OF NEW ENTRANTS
3.5.2 THREAT OF SUBSTITUTES
3.5.3 BARGAINING POWER OF SUPPLIERS
3.5.4 BARGAINING POWER OF BUYERS
3.5.5 RIVALRY AMONG EXISTING COMPETITORS
3.6 REGULATORY AFFAIRS
3.6.1 NORTH AMERICA
3.6.2 EUROPE
3.6.3 CHINA
3.6.4 JAPAN
3.6.5 INDIA
3.6.6 LATIN AMERICA
3.7 PATENT ANALYSIS
3.8 FUNDING SCENARIO
3.9 COLLABORATION, JOINT VENTURE, PARTNERSHIP, AGREEMENT
3.10 MARKET SHARE ANALYSIS
4 GENOME EDITING GLOBAL MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.2 ZINC FINGER NUCLEASE (ZFN)
4.3 TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALEN)
4.4 CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR/CAS9)
4.4.1 WT CRISPR/CAS9
4.4.2 CRISPR/CAS9 NICKASE
4.4.3 CRISPR DCAS9
4.5 OTHERS
4.5.1 RECOMBINANT ADENO-ASSOCIATED VIRUS (R AAV)
4.5.2 PIGGYBAC TRANSPOSASE AND SLEEPING BEAUTY TRANSPOSON
4.5.3 ARCUS (HOMING ENDONUCLEASE) AND MEGATAL
4.5.4 TARGATT AND RAPID TRAIT DEVELOPMENT SYSTEM (RTDS)
5 GENOME EDITING GLOBAL MARKET, BY APPLICATION
5.1 INTRODUCTION
5.2 BASIC RESEARCH
5.2.1 TRANSCRIPTION ACTIVATION/REPRESSION
5.2.2 GENOMIC SCREENING
5.2.3 GENOMIC VISUALIZATION
5.3 PLANT BIOTECHNOLOGY/AGRICULTURE
5.4 ANIMAL BIOTECHNOLOGY
5.4.1 ANIMAL HEALTH
5.4.2 LIVESTOCK
5.4.3 OTHER
5.5 DRUG DISCOVERY AND DEVELOPMENT
5.5.1 PRE-CLINICAL
5.5.2 CLINICAL
6 GENOME EDITING GLOBAL MARKET, BY PRODUCTS AND SERVICES
6.1 INTRODUCTION
6.2 REAGENTS, ENZYMES AND CONSUMABLES
6.2.1 GENOME EDITING TOOLS AND KITS
6.2.2 DELIVERY TOOLS
6.2.3 OTHER REAGENTS, ENZYMES AND CONSUMABLES
6.3 CELL LINES AND ANIMAL MODELS
6.4 GENOME EDITING SERVICES
6.5 INSTRUMENTS
6.6 SOFTWARE
7 GENOME EDITING GLOBAL MARKET, BY END USERS
7.1 INTRODUCTION
7.2 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
7.3 PLANT BIOTECHNOLOGY COMPANIES
7.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
7.5 OTHERS
7.5.1 ANIMAL BIOTECHNOLOGY
7.5.2 CONTRACT RESEARCH ORGANIZATIONS (CRO)
8 GENOME EDITING GLOBAL MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 U.S.
8.3 EUROPE
8.4 ASIA-PACIFIC
8.4.1 CHINA
8.4.2 JAPAN
8.4.3 INDIA
8.5 REST OF THE WORLD (ROW)
8.5.1 LATIN AMERICA
8.5.2 MIDDLE EAST
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.1.1 LICENSING AGREEMENT AND OTHERS AS A MAJOR GROWTH
STRATEGY OF MARKET PLAYERS
9.2 LICENSING AGREEMENT
9.3 OTHER DEVELOPMENTS
9.4 AGREEMENT/COLLABORATION/PARTNERSHIP/JOINT VENTURE
9.5 APPROVAL
9.6 NEW PRODUCT LAUNCH
9.7 ACQUISITIONS
10 MAJOR COMPANIES
10.1 APPLIED STEMCELL INC.
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCT PORTFOLIO
10.1.4 KEY DEVELOPMENTS
10.1.5 BUSINESS STRATEGY
10.1.6 SWOT ANALYSIS
10.2 CELLECTIS S.A.
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCT PORTFOLIO
10.2.4 KEY DEVELOPMENTS
10.2.5 BUSINESS STRATEGY
10.2.6 SWOT ANALYSIS
10.3 GENSCRIPT BIOTECH CORPORATION
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCT PORTFOLIO
10.3.4 KEY DEVELOPMENTS
10.3.5 BUSINESS STRATEGY
10.3.6 SWOT ANALYSIS
10.4 HORIZON DISCOVERY GROUP, PLC
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCT PORTFOLIO
10.4.4 KEY DEVELOPMENTS
10.4.5 BUSINESS STRATEGY
10.4.6 SWOT ANALYSIS
10.5 MERCK KGAA
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCT PORTFOLIO
10.5.4 KEY DEVELOPMENTS
10.5.5 BUSINESS STRATEGY
10.5.6 SWOT ANALYSIS
10.6 ORIGENE TECHNOLOGIES, INC.
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCT PORTFOLIO
10.6.4 KEY DEVELOPMENTS
10.6.5 BUSINESS STRATEGY
10.6.6 SWOT ANALYSIS
10.7 SANGAMO BIOSCIENCES
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCT PORTFOLIO
10.7.4 KEY DEVELOPMENTS
10.7.5 BUSINESS STRATEGY
10.7.6 SWOT ANALYSIS
10.8 SYSTEM BIOSCIENCES
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCT PORTFOLIO
10.8.4 KEY DEVELOPMENTS
10.8.5 BUSINESS STRATEGY
10.8.6 SWOT ANALYSIS
10.9 THERMO FISHER SCIENTIFIC INC.
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCT PORTFOLIO
10.9.4 KEY DEVELOPMENTS
10.9.5 BUSINESS STRATEGY
10.9.6 SWOT ANALYSIS
10.10 TRANSPOSAGEN
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCT PORTFOLIO
10.10.4 KEY DEVELOPMENTS
10.10.5 BUSINESS STRATEGY
10.10.6 SWOT ANALYSIS
LIST OF TABLES
Table 1 GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 2 GENOME EDITING GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2014-2022) ($MN)
Table 3 ZFN GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 4 TALEN GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 5 CRISPR GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 6 OTHERS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 7 GENOME EDITING GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 8 BASIC RESEARCH GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 9 PLANT BIOTECHNOLOGY/AGRICULTURE GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 10 ANIMAL BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 11 DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 12 DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 13 PRE-CLINICAL GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 14 CLINICAL GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 15 GENOME EDITING GLOBAL MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 16 REAGENTS, ENZYMES AND CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 17 CELL LINES AND ANIMAL MODELS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 18 GENOME EDITING SERVICES GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 19 INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 20 GENOME EDITING SOFTWARE GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 21 GENOME EDITING GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 22 ACADEMIC AND GOVERNENMENT INSTITUTIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 23 PLANT BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 24 PHARMACEUTICAL AND BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 25 OTHERS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 26 GENOME EDITING, GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 27 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 28 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 29 NORTH AMERICAN DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 30 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 31 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 32 EUROPEAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 33 EUROPEAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 34 EUROPEAN DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 35 EUROPEAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 36 EUROPE GENOME EDITING MARKET REVENUE, BY END USERS, (2014-2022) ($MN)
Table 37 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 38 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 39 ASIA-PACIFIC DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 40 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 41 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 42 ROW GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2014-2022) ($MN)
Table 43 ROW GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 44 ROW DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 45 ROW GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 46 ROW GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 47 LICENSING AGREEMENT (2015-2016)
Table 48 OTHER DEVELOPMENTS (2015-2016)
Table 49 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2015-2016)
Table 50 APPROVALS (2015-2016)
Table 51 NEW PRODUCT LAUNCH (2015-16)
Table 52 ACQUISITIONS (2015)
Table 53 CELLECTIS S.A.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 54 CELECTIS S.A.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 55 GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 56 GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 57 GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 58 HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 59 HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 60 HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 61 MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
Table 62 MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
Table 63 MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
Table 64 SANGAMO BIOSCIENCES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 65 SANGAMO BIOSCIENCES: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 66 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
Table 67 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
Table 68 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
Table 1 GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 2 GENOME EDITING GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2014-2022) ($MN)
Table 3 ZFN GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 4 TALEN GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 5 CRISPR GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 6 OTHERS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 7 GENOME EDITING GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 8 BASIC RESEARCH GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 9 PLANT BIOTECHNOLOGY/AGRICULTURE GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 10 ANIMAL BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 11 DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 12 DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 13 PRE-CLINICAL GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 14 CLINICAL GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 15 GENOME EDITING GLOBAL MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 16 REAGENTS, ENZYMES AND CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 17 CELL LINES AND ANIMAL MODELS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 18 GENOME EDITING SERVICES GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 19 INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 20 GENOME EDITING SOFTWARE GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 21 GENOME EDITING GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 22 ACADEMIC AND GOVERNENMENT INSTITUTIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 23 PLANT BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 24 PHARMACEUTICAL AND BIOTECHNOLOGY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 25 OTHERS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 26 GENOME EDITING, GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Table 27 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 28 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 29 NORTH AMERICAN DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 30 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 31 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 32 EUROPEAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 33 EUROPEAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 34 EUROPEAN DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 35 EUROPEAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 36 EUROPE GENOME EDITING MARKET REVENUE, BY END USERS, (2014-2022) ($MN)
Table 37 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 38 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 39 ASIA-PACIFIC DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 40 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 41 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 42 ROW GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2014-2022) ($MN)
Table 43 ROW GENOME EDITING MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 44 ROW DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 45 ROW GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2014-2022) ($MN)
Table 46 ROW GENOME EDITING MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 47 LICENSING AGREEMENT (2015-2016)
Table 48 OTHER DEVELOPMENTS (2015-2016)
Table 49 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2015-2016)
Table 50 APPROVALS (2015-2016)
Table 51 NEW PRODUCT LAUNCH (2015-16)
Table 52 ACQUISITIONS (2015)
Table 53 CELLECTIS S.A.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 54 CELECTIS S.A.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 55 GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 56 GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 57 GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 58 HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 59 HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 60 HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 61 MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
Table 62 MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
Table 63 MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
Table 64 SANGAMO BIOSCIENCES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 65 SANGAMO BIOSCIENCES: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 66 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
Table 67 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
Table 68 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
LIST OF FIGURES
Figure 1 GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Figure 2 RESEARCH METHODOLOGY: GENOME EDITING GLOBAL MARKET
Figure 3 GENOME EDITING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
Figure 4 GENOME EDITING GLOBAL MARKET: FORECASTING MODEL
Figure 5 GENOME EDITING GLOBAL MARKET: MARKET CRACKDOWN & DATA TRIANGULATION
Figure 6 GENOME EDITING GLOBAL MARKET: MARKET SEGMENTATION
Figure 7 MARKET DYNAMICS
Figure 8 GENOME EDITING GLOBAL MARKET: PORTER’S ANALYSIS
Figure 9 GENOME EDITING GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2016)
Figure 10 APPLICATIONS WISE FUNDING ($MN) IN GENOME EDITING MARKET (SINCE-2015)
Figure 11 ADOPTION OF DIFFERENT GENOME EDITING TECHNOLOGIES BY DIFFERENT COMPANIES
Figure 12 SELECTED DEALS IN GENOME EDITING MARKET (SINCE-2015)
Figure 13 GLOBAL GENOME EDITING MARKET SHARE ANALYSIS BY KEY PLAYERS (2015) (%)
Figure 14 GLOBAL GENOME EDITING MARKET REVENUE BY TECHNOLOGY, (2015 V’S 2022) ($MN)
Figure 15 GENOME EDITING GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 16 GLOBAL GENOME EDITING MARKET REVENUE BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
Figure 17 GENOME EDITING GLOBAL MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
Figure 18 GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN), CAGR (%)
Figure 19 NORTH AMERICAN GENOME EDITING MARKET REVENUE BY TECHNOLOGY TYPE, (2015 V’S 2022) ($MN)
Figure 20 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 21 NORTH AMERICAN GENOME EDITING MARKET REVENUE BY PRODUCTS AND SERVICE, (2015 V’S 2022) ($MN)
Figure 22 NORTH AMERICAN GENOME EDITING MARKET REVENUE BY END USERS, (2015 V’S 2022) ($MN)
Figure 23 EUROPEAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2015 V'S 2022) ($MN)
Figure 24 EUROPEAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 25 EUROPEAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
Figure 26 EUROPEAN GENOME EDITING MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
Figure 27 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2015 V’S 2022) ($MN)
Figure 28 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 29 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
Figure 30 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
Figure 31 ROW GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2015 V’S 2022) ($MN)
Figure 32 ROW GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 33 ROW GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
Figure 34 ROW GENOME EDITING MARKET REVENUE, BY END USER, (2015 V'S 2022) ($MN)
Figure 35 KEY GROWTH STRATEGIES (2015-2016)
Figure 36 SWOT: APPLIED STEMCELL INC.
Figure 37 SWOT: CELLECTIS S.A.
Figure 38 SWOT: GENSCRIPT BIOSCIENCES CORPORATION
Figure 39 SWOT: HORIZON DISCOVERY GROUP, PLC
Figure 40 SWOT: MERCK KGAA
Figure 41 SWOT: ORIGENE TECHNOLOGIES
Figure 42 SWOT: SANGAMO BIOSCIENCES
Figure 43 SWOT: SYSTEM BIOSCIENCES
Figure 44 SWOT: THERMO FISHER SCIENTIFIC
Figure 45 SWOT: TRANSPOSAGEN
Figure 1 GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Figure 2 RESEARCH METHODOLOGY: GENOME EDITING GLOBAL MARKET
Figure 3 GENOME EDITING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
Figure 4 GENOME EDITING GLOBAL MARKET: FORECASTING MODEL
Figure 5 GENOME EDITING GLOBAL MARKET: MARKET CRACKDOWN & DATA TRIANGULATION
Figure 6 GENOME EDITING GLOBAL MARKET: MARKET SEGMENTATION
Figure 7 MARKET DYNAMICS
Figure 8 GENOME EDITING GLOBAL MARKET: PORTER’S ANALYSIS
Figure 9 GENOME EDITING GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2016)
Figure 10 APPLICATIONS WISE FUNDING ($MN) IN GENOME EDITING MARKET (SINCE-2015)
Figure 11 ADOPTION OF DIFFERENT GENOME EDITING TECHNOLOGIES BY DIFFERENT COMPANIES
Figure 12 SELECTED DEALS IN GENOME EDITING MARKET (SINCE-2015)
Figure 13 GLOBAL GENOME EDITING MARKET SHARE ANALYSIS BY KEY PLAYERS (2015) (%)
Figure 14 GLOBAL GENOME EDITING MARKET REVENUE BY TECHNOLOGY, (2015 V’S 2022) ($MN)
Figure 15 GENOME EDITING GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 16 GLOBAL GENOME EDITING MARKET REVENUE BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
Figure 17 GENOME EDITING GLOBAL MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
Figure 18 GENOME EDITING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN), CAGR (%)
Figure 19 NORTH AMERICAN GENOME EDITING MARKET REVENUE BY TECHNOLOGY TYPE, (2015 V’S 2022) ($MN)
Figure 20 NORTH AMERICAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 21 NORTH AMERICAN GENOME EDITING MARKET REVENUE BY PRODUCTS AND SERVICE, (2015 V’S 2022) ($MN)
Figure 22 NORTH AMERICAN GENOME EDITING MARKET REVENUE BY END USERS, (2015 V’S 2022) ($MN)
Figure 23 EUROPEAN GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2015 V'S 2022) ($MN)
Figure 24 EUROPEAN GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 25 EUROPEAN GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
Figure 26 EUROPEAN GENOME EDITING MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
Figure 27 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY TECHNOLOGY, (2015 V’S 2022) ($MN)
Figure 28 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 29 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
Figure 30 ASIA-PACIFIC GENOME EDITING MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
Figure 31 ROW GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, (2015 V’S 2022) ($MN)
Figure 32 ROW GENOME EDITING MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 33 ROW GENOME EDITING MARKET REVENUE, BY PRODUCTS AND SERVICES, (2015 V’S 2022) ($MN)
Figure 34 ROW GENOME EDITING MARKET REVENUE, BY END USER, (2015 V'S 2022) ($MN)
Figure 35 KEY GROWTH STRATEGIES (2015-2016)
Figure 36 SWOT: APPLIED STEMCELL INC.
Figure 37 SWOT: CELLECTIS S.A.
Figure 38 SWOT: GENSCRIPT BIOSCIENCES CORPORATION
Figure 39 SWOT: HORIZON DISCOVERY GROUP, PLC
Figure 40 SWOT: MERCK KGAA
Figure 41 SWOT: ORIGENE TECHNOLOGIES
Figure 42 SWOT: SANGAMO BIOSCIENCES
Figure 43 SWOT: SYSTEM BIOSCIENCES
Figure 44 SWOT: THERMO FISHER SCIENTIFIC
Figure 45 SWOT: TRANSPOSAGEN
